Increased serum MFAP4 was observed in hepatocellular carcinoma patients [101,102] and MFAP4 was suggested as a potential biomarker in the serous ovarian cancer due to high expression and association with chemoresistance [103]. Here, MFAP4 is linked to hepatocellular carcinoma.